Psybio Therapeutics, Inc. v. Corbin

District Court, N.D. Illinois·Decided January 27, 2021·No. 1:20-cv-03340·Unknown

Opinion

THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

) PSYBIO THERAPEUTICS, INC., )

) Plaintiff, ) ) v. ) ) RICHARD CORBIN ) ) Defendant. No. 20 C 3340 ) __________________________________ ) Judge Virginia M. Kendall RICHARD CORBIN, ) ) Counter-Plaintiff, ) ) v. )

PSYBIO THERAPEUTICS, INC., ) ) Counter-Defendant. )

MEMORANDUM OPINION AND ORDER Psybio is a research and development company concentrating on the development of biosynthetic psychoactive compounds that offer a new paradigm of treatment for mental health issues. Psilocybin is a naturally occurring psychedelic prodrug compound that is produced by species of fungus—or more commonly described as psychedelic mushrooms or magic mushrooms. Richard Corbin formed and incorporated Psybio in January 2020. A few weeks later, and by his consent, Corbin named Evan Levine, Ross Carmel and himself as the directors of the company. A few weeks after that, on February 7, 2020, the Board of Directors issued 31,200,000 shares of the company: 10 million to Levance Prospects LLC, an entity owned by Levine; 10 million to Robert Nathan; 10 million to Colony Capital LLC, an entity owned and controlled by Corbin; and 1.2 million to Carmel, Milazzo, & DiChiara LLP. Shortly after setting up the company, Corbin obtained websites and domain names for Psybio using his own name. By April, the directors were at logger heads. On the one side was Corbin who had successfully obtained a partnership with a professor from Miami University and had entered into a letter of intent wherein Psybio would sponsor the professor’s research and possible commercial medical uses of psilocybin. On the other side was Levine and Carmel who wanted

a private equity firm in Toronto, Canada to invest in the company. Corbin did not like the idea of the potential deal because it would permit the Canadian company to receive nearly one-third of Psybio’s stock through the acquisition of extra shares that were more valuable than the investment itself. Meanwhile, Carmel and Levine had formed another entity called PsyBio Life Sciences and they sought to get Corbin to reduce his shares. When he refused, they voted to dissolve the entity only to come back later to say they could not have done so but they fired him from his board position. The other directors had confronted Corbin regarding what they believed to be wrongful conduct and a standoff began with Corbin essentially refusing to provide any services to Psybio until the Directors provided him with a lucrative employment contract and substantial severance package and the Directors efforts to

dissolve the entity and move Corbin out of his position. Through a serious of actions, the Directors first attempted to dissolve Psybio but then realized they could not do that because they needed to so at a shareholders’ meeting. Next, they fired Corbin from the board on May 6, 2020 for “misconduct” including interfering with Psybio’s relationship with Miami University and refusing to provide passwords and domaine names to them. This led to Psybio filing suit on June 5, 2020 for breach of fiduciary duty and equitable relief. Of course, the battle did not end there. Corbin counter-sued alleging that Psybio had wrongfully forced him out; created a stock split that would significantly reduce his shares; and intended to merge with another company and failed to notify him of the merger. He alleged unfair dealing, appraisal, conversion and declaratory judgment among other claims. On January 19, 2021, nearly one year to the day of the incorporation of Psybio, Corbin moved for a temporary restraining order alleging immediate harm from the pending merger that

cannot be remedied without the issuance of an injunction. The Court held a hearing on January 22 and continued on January 25, 2021. For the following reasons, the Court denies Corbin’s motion for a TRO. LEGAL STANDARD The standard for the issuance of a TRO is the same as that required to issue a preliminary injunction. See Merritte v. Kessel, 561 Fed.Appx. 546, 548 (7th Cir.2014). To obtain a preliminary injunction, the movant must demonstrate (1) a likelihood of success on the merits, (2) that he or she will suffer irreparable harm absent injunctive relief, and (3) that he or she has no adequate remedy at law. Smith v. Executive Dir. of Ind. War Mem'ls Comm'n, 742 F.3d

282, 286 (7th Cir.2014); Incredible Techs., Inc. v. Virtual Techs., Inc., 400 F.3d 1007, 1011 (7th Cir.2005). If the moving party meets this threshold showing, the Court “must weigh the harm that the plaintiff will suffer absent an injunction against the harm to the defendant from an injunction.” GEFT Outdoors, LLC v. City of Westfield, 922 F.3d 357, 364 (7th Cir. 2019) (internal quotations omitted). The Court must also consider whether the injunction is in the public interest, including any effects granting the relief may have on non-parties. Courthouse News Serv. v. Brown, 908 F.3d 1063, 1068 (7th Cir. 2018). DISCUSSION The first issue to address is whether emergency relief should be granted. Emergency relief is rare and it is preserved for those circumstances when the preservation of the status

quo is essential in order to prevent a party from suffering a harm that cannot be redressed in some monetary way. Of course, the parties have been litigating now for eight months and have been in discovery to get to the bottom of their issues. The usual course of litigation would require them to finish that work and then file a dispositive motion if they are able. But stopping that usual litigation path for an emergency must truly be a situation where monetary damages are simply insufficient to redress a harm. Corbin alleges that he seeks emergency relief now, eight months into the litigation, because the merger is expected to take place by the end of February and he will be harmed irreparably from it. Yet, the merger was the main basis for the dispute in the first place. All the way back in April 2020, Corbin was aware that Levine and Carmel were seeking to have a Canadian private equity firm invest in PsyBio. When the lawsuit was filed, he counter-

claimed alleging that his shares were being diluted and that he would not have a say in the direction of the company. Then in October 2020, there was a public announcement about the venture. Through discovery, Corbin has sought to get the details of the agreement and has not been able to do so. He did not file this emergency motion until January of 2021. Nothing new has changed since the suit was filed in that he was aware of the intended merger and stock split in April and even had public verification by October. Simply because he wants information regarding that merger is not a sufficient change in circumstances to qualify for emergency relief. This could be the end of discussion here but the Court will address why even if there were an emergency, Corbin is not entitled to relief. Corbin must have a likelihood of success on the merits. His claims involve unfair dealing, conversion, and declaratory judgment among others. When the Court began the hearing on a Friday, the presentation of the evidence to show that Corbin is entitled to relief was inconclusive and, at best, confusing. The Court gave Corbin an opportunity to file more fulsome briefs and present more evidence. This led to the second day of the hearing which

Free access — add to your briefcase to read the full text and ask questions with AI

Psybio Therapeutics, Inc. v. Corbin, (N.D. Ill. 2021).

Psybio Therapeutics, Inc. v. Corbin (Psybio Therapeutics, Inc. v. Corbin) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Courthouse News Services v. Dorothy Brown
908 F.3d 1063 (Seventh Circuit, 2018)
Geft Outdoors, LLC v. City of Westfield
922 F.3d 357 (Seventh Circuit, 2019)
Merritte v. Kessel
561 F. App'x 546 (Seventh Circuit, 2014)